Product Description: BI 2536 is a dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively[1]. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription[4].
Applications: Cancer-Kinase/protease
Formula: C28H39N7O3
References: [1]Lénárt P, et al. The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1. Curr Biol. 2007 Feb 20;17(4):304-15./[2]Chen L, et al. BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. ACS Med Chem Lett. 2015 May 18;6(7):764-9./[3]Steegmaier M, et al. BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo. Current Biology (2007), 17(4), 316-322./[4]Malik N, et al. Suppression of IFN β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members. Biochem J. 2015 Jun 15;468(3):363-72.
CAS Number: 755038-02-9
Molecular Weight: 521.65
Compound Purity: 99.95
Research Area: Cancer
Solubility: 0.1 M HCl : 25 mg/mL (ultrasonic;adjust pH to 4 with HCl)/DMSO : 65 mg/mL (ultrasonic)
Target: Apoptosis;Epigenetic Reader Domain;Polo-like Kinase (PLK)
Deutsch
English
